From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|November 29, 2014
Pharmacy Times Asks a Burmans Pharmacist: How Do You Build Patient Trust?
For Vince Canzanese, RPh, director of compounding for Burmans Pharmacy, building patient trust relies on a key factor: not allowing a mailman to become the pharmacist.
Advertisement
For Vince Canzanese, RPh, director of compounding for
“Primarily, we build trust with the patients because we’re a community-based organization,” he says. “We’re here, it’s brick-and-mortar, someone can come in and see me, they know who they’re talking to. It’s not just a voice on the phone.”
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5